Page 202 - HA Convention 2016 [Full Version]

HOSPITAL AUTHORITY CONVENTION 2016 Corporate Scholarship Presentations

C2.3 Genetics and New Technology 13:15 Room 428

Surgical Treatment for Infertility
Choi SSN
Department of Obstetrics and Gynaecology, United Christian Hospital, Hong Kong

Assisted reproduction technology (ART) has become a standard treatment for infertile couples. Improved embryo quality has
contributed to increased success rates obtained over the years. However, implantation rates still remain lower than expected.
The uterus, which plays an important role in implantation, has been frequently neglected. Treating abnormalities in the uterine
cavity, such as polyps, fibroids, septa or adhesions, might increase the chance of pregnancy either spontaneously or after
assisted reproductive techniques. However, there is no structured reproductive surgery training in Hong Kong.

The Hysteroscopic Centre of Fuxing Hospital Capital Medical University of Medical Sciences was established in 1990 by
Professor Enlan Xia. Professor Xia is the pioneer of gynaecological endoscopic surgery in China. She has been widely
recognised as the “Mother of Hysteroscopy” in China in view of her substantial contribution to the development of
hysteroscopic surgery in China since 1990.

With the dedicated effort of Professor Xia, the Hysteroscopic Centre has become one of the best gynaecology endoscopic
centres in China. Its reputation has attracted patients from all over China to seek treatment for their recurrent miscarriage or
infertility. Additionally, its most advanced gynaecological endoscopic technique has made it one of the most preferred places
for training attachments of gynaecologists from different parts of China.

The speaker has received extensive training in the Hysteroscopic Centre in 2015. First hand experiences in various advanced
hysteroscopic surgery from the Mother of Hysteroscopy was learned. In this presentation, experience in hysteroscopic
training at the Hysteroscopic Centre of Fuxing Hospital will be shared and discussed.

C2.4 Genetics and New Technology 13:15 Room 428

Wednesday, 4 May Transitional Care in Inborn Metabolic Diseases
Sheng B
Medicine and Geriatrics, Princess Margaret Hospital, Hong Kong

Moving from a child-centred, parent-dominated paediatric service to an adult-oriented and self-responsible healthcare
is a big difficult step for adolescents or young adults with chronic diseases. For inborn metabolic diseases (IMDs), one
unique problem is the lack of an appropriate adult medical service to refer. For years, IMDs belongs to the expertise of
paediatricians and adult physicians do not bother these “inborn” problems. Credits to our paediatric colleagues, with the
advances in knowledge and treatment, these children with IMDs now become adult, and many of them enjoy a productive
life. Their growing demand for a quality continued care, with attention to their specific new grown-up issues in reproduction,
occupation, etc., makes a specialised adult IMDs service an inevitable mission.

Historically, adult metabolic service usually started with physician’s personal curiosity in the disease. The lack of a critical
mass greatly jeopardised skill development, training, inter-disciplinary collaborations, scientific research and exchange of
knowledge; and the sustainability of these small scale service would often be affected by come and go of a key personnel. It
becomes obvious that a coordinated, centralised, and specialist-led service should emerge as a potential solution. In the past
two decades, many integrated, centralised IMD centres have been established in developed countries. Their birth witnesses
the revolutionary change brought about by advances in newborn screening, which picks up many IMDs at early stage where
appropriate nutritional or drug therapy have greatly improved their long term outlooks, and the increasingly recognised IMDs
first presenting in adults.

Princess Margaret Hospital is the first hospital in Hong Kong committed to adult IMDs with specialist integrated clinic and
ambulatory care. We are also responsible for all the enzyme replacement therapies for adult lysosomal storage diseases. In
this talk, our existing ground work, future plans, vision and commitment to adult IMDs will be explained.

200